Since baseline of March 2017, community health centers have demonstrated aggregate performance improvements in lifestyle measures including body mass index, tobacco, and depression screenings with documented follow-up plans as well as on prescription measures, including angiotensin converting enzyme/angiotensin receptor blocker and statin prescription rates, among patients aged 55 through 75 with diabetes. This evidence concerns the gene ACE and diabetes mellitus.